

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
Sheraton College Park North Hotel, Chesapeake Ballroom
4095 Powder Mill Road, Beltsville, Maryland
March 29, 2017

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren Tesh, PharmD, BCPS

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Harold J. Burstein, MD, PhD

Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Bernard F. Cole, PhD

Professor
Department of Mathematics and Statistics
University of Vermont
Burlington, Vermont

Heidi D. Klepin, MD, MS

Associate Professor of Internal Medicine
Section of Hematology and Oncology
Wake Forest University Health Sciences
Winston Salem, North Carolina

Courtney J. Preusse, MA

(Consumer Representative)
Research Administrator and Patient Advocate
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Bruce J. Roth, MD

(Chairperson)
Professor of Medicine
Division of Oncology
Washington University School of Medicine
St. Louis, Missouri

Alice T. Shaw, MD, PhD

Director, Center for Thoracic Cancers
Massachusetts General Hospital
Associate Professor, Harvard Medical School
Boston, Massachusetts

Thomas S. Uldrick, MD, MS

Clinical Director
HIV & AIDS Malignancy Branch
Center for Cancer Research
National Cancer Institute
Bethesda, Maryland

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP

Executive Medical Director, Amgen Oncology
Therapeutic Area Head, US Medical Organization
Thousand Oaks, California

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
March 29, 2017

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Arthur F. Harralson, PharmD, BCPS

Professor and Chair
Department of Pharmacogenomics and
Associate Dean for Research
Bernard J. Dunn School of Pharmacy
Shenandoah University
Pharmacogenomics Program
School of Medicine and Health Sciences
The George Washington University
Virginia Science and Technology Campus
Ashburn, Virginia

Paul V. Majkowski, JD

(Patient Representative)
Uniondale, New York

Adel Karara, BPharm, PhD, FCP

Associate Professor of Pharmaceutical Sciences
University of Maryland at Eastern Shore
Princess Anne, Maryland

Scott Waldman, MD, PhD, FCP, FAHA

Director, Gastrointestinal Cancer Program of the
Sidney Kimmel Cancer Center
Samuel M.V. Hamilton Professor of Medicine
Chair, Department of Pharmacology and
Experimental Therapeutics
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director
Office of Hematology Oncology Products (OHOP)
Office of New Drugs (OND), CDER, FDA

R. Angelo de Claro, MD

Medical Team Leader
DHP, OHOP, OND, CDER, FDA

Lanre Okusanya, PharmD, MS

Clinical Pharmacologist
Division of Clinical Pharmacology V (DCPV)
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS), CDER, FDA

Ann Farrell, MD

Director
Division of Hematology Products (DHP)
OHOP, OND, CDER, FDA

Alexandria Schwarsin, MD

Medical Officer
DHP, OHOP, OND, CDER, FDA

Jingjing Ye, PhD

Mathematical Statistician
Division of Biometrics V (DBV)
Office of Biometrics (OB), OTS, CDER, FDA